our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Meningioma

News alerts, weekly reports and conference planners

Related cancers:

‹

Pituitary Gland Carcinoma (10)

Pituitary Gland Carcinoma (10)

›

Consensus Radiation Treatment Planning Guidelines Utilizing (68)Ga-DOTATATE PET/CT for Resected Meningiomas. (PubMed, Int J Radiat Oncol Biol Phys)

This report provides consensus target volume delineation guidelines for meningiomas receiving postoperative radiation in common clinical situations. Integration of these guidelines into clinical practice may allow for more precise biomarker-guided radiation treatments and standardize radiotherapy on future meningioma clinical trials.

3 days ago

Journal

SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. (PubMed, JCO Precis Oncol)

This protocol did not meet its prespecified primary end point. Defactinib monotherapy had limited clinical activity in this cohort of previously treated patients with solid tumors exhibiting NF2 loss.

4 days ago

P2 data • Journal

NF2 (Neurofibromin 2)

NF2 mutation

defactinib (VS-6063)

A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma (clinicaltrials.gov)

P2, N=56, Not yet recruiting, Shanghai Runshi Pharmaceutical Technology Co., Ltd

4 days ago

New P2 trial

SYHA1813

Immunohistochemical Staining Properties of Osteopontin and Ki-67 in Feline Meningiomas. (PubMed, Animals (Basel))

The overall high expressions of osteopontin and Ki-67 may help explain the tendency for recurrence of feline meningioma. The human WHO grading system may not be sufficient to accurately estimate the clinical behavior of meningioma in this species.

5 days ago

Journal

SPP1 (Secreted Phosphoprotein 1)

Flow Cytometry Analyses of Meningioma Immune Cell Composition Using a Short, Optimized Digestion Protocol. (PubMed, Cancers (Basel))

We successfully optimized a protocol for generating single-cell suspensions with viable immune cells from meningioma tissues, revealing infiltrating antigen-presenting cells with an immunosuppressive phenotype, and lymphocytes. This short protocol allows advanced analyses of tumor-infiltrating cells using techniques such as single-cell RNA sequencing and flow cytometry, which require live, dissociated cells.

5 days ago

Journal • Immune cell

HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • NCAM1 (Neural cell adhesion molecule 1) • CD14 (CD14 Molecule)

A Study of ONC201 for Refractory Meningioma (clinicaltrials.gov)

P2, N=27, Suspended, University of Nebraska | Not yet recruiting --> Suspended

6 days ago

Trial suspension

dordaviprone (ONC201)

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study (clinicaltrials.gov)

P=N/A, N=70, Recruiting, Emory University | Trial completion date: Oct 2025 --> Dec 2031 | Trial primary completion date: Oct 2024 --> Dec 2030

9 days ago

Trial completion date • Trial primary completion date

10d

Metastasis of WHO Grade II Meningioma With Subsequent Pathological T12 Fracture: A Case Report. (PubMed, JBJS Case Connect)

This is one of few documented cases of spinal metastatic meningioma causing pathological fracture and the first to detail surgical management and longitudinal follow-up. Applying the neurologic, oncologic, mechanical, and systemic decision framework to this rare presentation, the patient was indicated for the selected surgical approach, yielding short-term improvement of patient outcome and neurologic deficit.

10 days ago

Journal

SSTR2 (Somatostatin Receptor 2)

11d

CoDeB-Rad: Measuring and Mapping Cognitive Decline After Brain Radiosurgery (clinicaltrials.gov)

P=N/A, N=80, Recruiting, University of Nottingham | Not yet recruiting --> Recruiting

11 days ago

Enrollment open • Surgery

12d

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma (clinicaltrials.gov)

P2, N=27, Recruiting, Northwestern University | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Sep 2026

12 days ago

Trial completion date • Trial primary completion date

Avastin (bevacizumab)

14d

Primary intracranial DICER1-mutant sarcoma: a clinicopathological analysis of seven cases (PubMed, Zhonghua Bing Li Xue Za Zhi)

Primary intracranial DICER1-mutant sarcoma is a rare tumor. Understanding its morphological characteristics, immunohistochemical and molecular markers and differential diagnosis is crucial to avoid misdiagnosis and to improve diagnostic accuracy of this tumor.

14 days ago

Retrospective data • Journal

TP53 (Tumor protein P53) • ATRX (ATRX Chromatin Remodeler) • DICER1 (Dicer 1 Ribonuclease III) • SALL4 (Spalt Like Transcription Factor 4)

TP53 mutation

16d

Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study (clinicaltrials.gov)

P=N/A, N=54, Completed, Post Graduate Institute of Medical Education and Research, Chandigarh

16 days ago

New trial • FDG PET

20d

A two-site combined prediction model based on HOXA9 DNA methylation for early screening of risks of meningioma progression (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)

High HOXA9 methylation level is a predictor for poor prognosis of meningiomas, and the combined prediction model based on its CpG sites provides a new approach to early screening of meningioma patients at risk of progression.

20 days ago

Journal • Epigenetic controller

HOXA9 (Homeobox A9)

HOXA9 methylation

20d

Neurofibromatosis type 2-related schwannomatosis - An update. (PubMed, Semin Pediatr Neurol)

Careful dermatologic, ophthalmologic, and neurologic examination can identify signs of NF2-SWN to allow timely initiation of disease specific treatment. Most patients benefit from multimodal treatment, including surgery.

20 days ago

Review • Journal

NF2 (Neurofibromin 2)

20d

Neurofibromatosis Type 2 Presenting as Symptomatic Gallbladder Hydrops: A Rare Case Report and Literature Review. (PubMed, Case Rep Pediatr)

This case helps shed light on unusual NF2 symptoms and underscores the importance of recognizing atypical presentations for timely intervention and management. It also adds value to a multidisciplinary approach in diagnosing and managing NF2.

20 days ago

Review • Journal

NF2 (Neurofibromin 2)

22d

Development and Validation of a Machine Learning Radiomics Model based on Multiparametric MRI for Predicting Progesterone Receptor Expression in Meningioma: A Multicenter Study. (PubMed, Acad Radiol)

The XGBoost combined model, utilizing multiparametric MRI, shows promise for predicting PR expression in meningioma patients.

22 days ago

Clinical • Journal • Machine learning

PGR (Progesterone receptor)

23d

Establishment of a novel benign meningioma cell line spontaneously immortalized under hypoxic conditions. (PubMed, Hum Cell)

Cultured under hypoxic conditions, this cell line showed fewer characteristics of cellular senescence, such as morphological changes, IL-6 secretion, and lower senescence-associated b-galactosidase activity, compared to the same cell line cultured under 20% O2 conditions. This immortalized non-transgenic cell line appears to reflect the characteristics of a genuine benign meningioma, potentially allowing the identification of new therapeutic targets and the development of novel therapies for benign meningiomas.

23 days ago

Preclinical • Journal

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • IL6 (Interleukin 6) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

CDKN2A deletion • TERT mutation

23d

Paediatric meningiomas: a multi-centre case series of 27 patients. (PubMed, Childs Nerv Syst)

The risk of grade 1 tumour recurrence was higher than within the adult population. This may be due to histological features of paediatric meningiomas differing from the adult population, and therefore, the WHO grading system may not be reflective of recurrence risk. Future molecular profiling and larger studies are required given the rarity of these cases.

23 days ago

Retrospective data • Journal

NF2 (Neurofibromin 2)

23d

Downregulation of lncRNA-MALAT1, Altered Immunohistochemical Expression of Cyclin D1 Protein and E-Cadherin Protein in Correlation to Meningioma Grades. (PubMed, Asian Pac J Cancer Prev)

lncRNA MALAT1 is downregulated in meningiomas and associated with increased aggressiveness. Overexpressed cyclin D1 and decreased E-cadherin expression are also associated with high grade meningioma.

23 days ago

Journal

CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)

CCND1 overexpression • CCND1 expression • CDH1 expression

23d

001_2024_BO2: Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation (clinicaltrials.gov)

P=N/A, N=100, Not yet recruiting, University Hospital Tuebingen

23 days ago

New trial

25d

"Rosary Sign" at Somatostatin Receptor PET in a Case of Recurrent Meningioma. (PubMed, Diagnostics (Basel))

This novel imaging pattern improved diagnostic accuracy by detailing disease extent and identifying additional lesions not visible via MRI. Given the failure of prior treatments and high SR expression, peptide receptor radionuclide therapy (PRRT) was proposed as a therapeutic option for the patient.

25 days ago

Journal

SSTR (Somatostatin Receptor)

26d

Flip-flop phenomenon on dual SSTR PET and amino acid PET in a case of recurrent meningioma with malignant transformation. (PubMed, Eur J Nucl Med Mol Imaging)

No abstract available

26 days ago

Journal

SSTR (Somatostatin Receptor)

27d

Optic nerve sheath meningioma detected by somatostatin receptor scintigraphy with [99mTc]Tc-Tektrotyd. (PubMed, Nucl Med Rev Cent East Eur)

This case study is one of the few that reports the use of a [99mTc]Tc-Tektrotyd single-photon emission computed tomography (SPECT/CT) scan for the non-invasive diagnosis of an orbital space-occupying tumor. This radiopharmaceutical can bind with high affinity to somatostatin receptor subtype 2, which is expressed in meningiomas.

27 days ago

Journal

SSTR (Somatostatin Receptor)

29d

EANO guideline on molecular testing of meningiomas for targeted therapy selection. (PubMed, Neuro Oncol)

In our assessment based on the established ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets) evidence level criteria, no molecular target reached ESCAT I ("ready for clinical use") classification and only mTOR pathway activation and NF2 alterations reached ESCAT II ("investigational") classification, respectively. Our evaluations may guide targeted therapy selection in clinical practice and clinical trial efforts and highlight areas for which additional research is warranted.

29 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • BAP1 (BRCA1 Associated Protein 1) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KLF4 (Kruppel-like factor 4)

HRD

30d

Primary and salvage radiosurgery for neurofibromatosis type 2-associated meningiomas. (PubMed, J Neurosurg)

In this case series, the LTC rates of both primary and salvage SRS exceeded 90%. However, nearly half of the patients required additional SRS for new untreated meningiomas. No significant differences in long-term LTC were found when comparing upfront versus salvage SRS for patients with NF2 meningiomas. These results establish SRS as a valuable and safe option for managing NF2-associated meningiomas.

30 days ago

Journal • Surgery

NF2 (Neurofibromin 2)

NF2 mutation

Functional annotation of the Hippo pathway somatic mutations in human cancers. (PubMed, Nat Commun)

Moreover, the schwannoma/meningioma-derived NF2 LOF mutations not only inhibit its tumor suppressive function in the Hippo pathway, but also gain an oncogenic role for NF2 by activating the VANGL-JNK pathway. Collectively, our study not only offers a rich somatic mutation resource for investigating the Hippo pathway in human cancers, but also provides a molecular basis for Hippo-based cancer therapy.

1 month ago

Journal

NF2 (Neurofibromin 2)

A novel mutation in SMARCB1 associated with adult Coffin-Siris syndrome and meningioma. (PubMed, Acta Biochim Biophys Sin (Shanghai))

Mechanistic studies suggest that this missense mutation may abnormally activate the MAPK signaling pathway, which is implicated in the pathogenesis of tumor progression and neurodevelopmental disorders. This is the first reported case of a germline mutation in the SMARCB1 gene associated with both CSS3 and meningioma, thereby expanding the phenotypic spectrum of SMARCB1-related disorders.

1 month ago

Journal

SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)

SMARCB1 mutation

A Shotgun Proteomic-Based Approach with a Q-Exactive Hybrid Quadrupole-Orbitrap High-Resolution Mass Spectrometer for the Assessment of Pesticide Mixture-Induced Neurotoxicity on a 3D-Developed Neurospheroid Model from Human Brain Meningiomas: Identification of Trityl-Post-Translational Modification. (PubMed, J Proteome Res)

The study also highlights the plausible role of pyrethroids to be implicated in the deleterious effects of pesticides in a mixture. To the best of our knowledge, our finding is the first in toxicoproteomics to deeply elucidate pesticides' molecular interactions and their ability to adduct proteins as a pivotal role in the neurotoxicity mechanism.

1 month ago

Journal

GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (clinicaltrials.gov)

P2, N=100, Active, not recruiting, Scott R. Plotkin, MD, PhD | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed • Pan tumor

NF2 (Neurofibromin 2)

Nerlynx (neratinib) • Alunbrig (brigatinib)

Presenting characteristics and clinical outcomes of idiopathic versus neurofibromatosis type 2-associated spinal meningiomas: a retrospective institutional experience. (PubMed, J Neurosurg Spine)

In this study of 166 surgically treated patients with SM, patients with NF2 presented earlier, experienced earlier progression, and experienced progression more frequently compared with those without NF2. Radiographic characteristics of tumors were relatively consistent between groups. While idiopathic SMs remain a relatively benign and highly manageable disease, considering tumor molecular characteristics and broader clinical history is paramount in providing efficacious and individualized patient care.

1 month ago

Clinical data • Retrospective data • Journal

NF2 (Neurofibromin 2)

NF2 mutation

Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations (AIOM 2024)

4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. The incidence of targettable molecular alterations in adult CNS tumor patients was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.

1 month ago

Clinical • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • POLE (DNA Polymerase Epsilon) • MDM2 (E3 ubiquitin protein ligase) • PTCH1 (Patched 1) • NF2 (Neurofibromin 2) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • BRCA2 mutation • BRCA1 mutation • TMB-H • PIK3CA mutation • MET amplification • ALK rearrangement • FGFR1 amplification • POLE mutation • NF1 mutation • MDM2 amplification • RET mutation • PTCH1 mutation • NF2 mutation • ROS1 mutation • BRCA mutation • ALK rearrangement + PIK3CA mutation • PTCH1 rearrangement • NTRK fusion

FoundationOne® CDx

Opdivo (nivolumab) • Yervoy (ipilimumab) • Alecensa (alectinib) • Erivedge (vismodegib)

Intracranial angioleiomyoma mimicking meningioma: an uncommon tumor with favorable outcome and frequent GJA4 mutation. (PubMed, Neurosurg Rev)

IALM had favorable outcome. Notably, IALMs frequently exhibited a GJA4 mutation, which was linked to the cavernous sinus and orbital locations, as well as PR expression.

1 month ago

Journal

PGR (Progesterone receptor) • GJA4 (Gap Junction Protein Alpha 4)

PGR expression

Differential Expression of Proteins and Genes at the Tumor-Brain Interface in Invasive Meningioma. (PubMed, Genes Chromosomes Cancer)

Pathway analyses identified significant links between DTX1 and RASGRF1 and key biological processes, including cell-cell adhesion, and signaling pathways including Notch, RAS, MAPK, and Rho. Higher expression of DTX1, RASGRF1, and Ki-67 in the brain-invasive area of meningiomas suggests that these proteins play a role in the process of brain invasion.

1 month ago

Journal

IL6 (Interleukin 6) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1)

Clinical study on the protective effect of preoperative lumbar drainage on the temporal lobe in petroclival meningioma resection by anterior transpetrous approach (ChiCTR2400090537)

P=N/A, N=160, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital Capital Medical University

1 month ago

New trial

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)

P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial primary completion date: Nov 2025 --> Nov 2027

1 month ago

Trial primary completion date

Lutathera (lutetium Lu 177 dotatate)

2ms

Detection of CDKN2A/B homozygous deletion by DNA methylation and DNA next generation sequencing: a comparison (SNO 2024)

All cases of homozygous deletion detected by NGS were also detected by DNA methylation. DNA methylation derived copy number assessment is more sensitive for CDKN2A/B homozygous deletion than next generation sequencing.

2 months ago

Next-generation sequencing • Epigenetic controller

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

CDKN2A deletion

NYU Langone Genome PACT assay

2ms

Proton Radiation For Meningiomas and Hemangiopericytomas (clinicaltrials.gov)

P1/2, N=53, Completed, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Completed

2 months ago

Trial completion

2ms

BAH2472: TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (clinicaltrials.gov)

P1/2, N=85, Recruiting, Essen Biotech | Not yet recruiting --> Recruiting

2 months ago

Enrollment open • Metastases

Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV

2ms

MicroRNA Analysis in Meningiomas with Different Degrees of Tissue Stiffness: A Potential Tool for Effective Preoperative Planning. (PubMed, Neurosurgery)

This research highlights the potential of miRNAs as biomarkers for determining meningioma tissue stiffness. Identifying specific miRNAs associated with tumor consistency could improve preoperative planning and patient prognosis. These findings pave the way for further exploration of miRNAs in the clinical assessment of meningiomas.

2 months ago

Journal

MIR31 (MicroRNA 31) • MIR34B (MicroRNA 34b)

2ms

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE (clinicaltrials.gov)

P4, N=20, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

2ms

H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications. (PubMed, Cancers (Basel))

Comprehending the role of H3K27me3 in CNS tumors is vital for advancing diagnostic tools and therapeutic interventions, with the goal of enhancing patient outcomes and quality of life. This review underscores the importance of ongoing investigations into H3K27me to refine and optimize management strategies for CNS tumors, paving the way for improved personalized medicine practices in oncology.

2 months ago

Review • Journal

H3-3A (H3.3 Histone A)

2ms

Immunohistochemical Expression of Tenascin-C in Canine Meningiomas. (PubMed, Vet Sci)

The reaction to TN-C was more significant in grade II and III tumors. The immunohistochemical findings of the current study suggest that TN-C can act as a stromal marker, mainly in grade II or III meningiomas.

2 months ago

Journal

VIM (Vimentin)